Navigation Links
Federal Guidelines Recommend New HIV Testing Method
Date:3/27/2013

MADISON, N.J., March 27, 2013 /PRNewswire/ -- A new test based on gene sequencing may be used to assess a patient's suitability for treatment with CCR5 antagonists, a class of HIV antiretroviral therapies, under new medical guidelines issued by the U.S. Department of Health and Human Services (DHHS).

The new genotypic test performs comparably to the standard culture-based phenotypic tropism technique for predicting response to CCR5 antagonists, but at about half the cost and with faster results, according to Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services. Quest Diagnostics is believed to offer the only genotypic HIV tropism test service in the United States to demonstrate comparable performance to the standard phenotypic method, previously the only method available nationally to help physicians predict response to CCR5 antagonists.

"CCR5 antagonists can be an important component of an effective and well-tolerated drug combination in some HIV-infected patients. Tropism testing is a requirement for using this drug class, and fast test results facilitate timely treatment decisions," said Jonathan M. Schapiro , MD, director of HIV/AIDS at the National Hemophilia Center, Tel Hashomer, Israel. "The inclusion of genotypic tropism testing by the DHHS HIV Guidelines is a very welcome development. Faster, cost-effective diagnostics are greatly needed to improve HIV management."

Testing for HIV tropism is necessary to predict response to CCR5 antagonist therapy. This therapy can help slow HIV disease progression in patients with a certain type of tropism, but offer no known clinical benefit in patients with other forms of tropism. Tropism refers to a type of cellular mechanism by which the HIV virus infects human cells.

The revised DHHS guidelines, titled Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, recommend "that a genotypic tropism assay be used as an alternative to a phenotypic tropism assay before initiation of a CCR5 antagonist-containing regimen." While prior HHS guidelines only recommended phenotypic assays, medical guidelines in Europe have supported genotypic HIV tropism tests since 2011.

The DHHS guidelines are available at: http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0/

"Genotyping is an example of how diagnostic innovation can expand clinical options for physicians while driving down costs for payers and patients," said Rick L. Pesano , M.D., Ph.D., medical director, infectious diseases, Quest Diagnostics. "We expect this method will provide the basis for developing additional diagnostic innovations that are clinically valuable and more cost effective than traditional techniques."

Quest Diagnostics has offered its clinical genotypic tropism test as a laboratory-developed test, named the Quest Diagnostics HIV-1 Tropism with Reflex to Ultradeep sequencing (UDS), since the spring of 2012. The company's advanced genetics laboratory in San Juan Capistrano, California, developed, validated and performs the test for clinicians in the United States. Quest Diagnostics can provide test results in as few as 10 business days, compared to average turnaround times of two to three weeks for phenotypic tests, and at roughly half the list price for the standard phenotypic test.

In late 2012, the peer-reviewed, open-access journal PLOS ONE published a study that found the Quest Diagnostics deep-sequencing genotypic method predicted response to HIV antiretroviral therapy as well as the industry's standard phenotypic test.

Quest Diagnostics has one of the most comprehensive HIV testing services menu in the diagnostic industry, with services that range from HIV screening, viral load, therapeutic monitoring, co-infection and resistance testing. In late 2012, the company launched the HIV proviral DNA tropism lab-developed test, which uses DNA extraction and sequencing followed by bioinformatic analysis to help enable genotypic tropism testing for patients with low or undetectable HIV-1 viral RNA (<1000 copies/mL).

About Quest Diagnostics
Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic information services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at QuestDiagnostics.com. Follow us at Facebook.com/QuestDiagnostics and Twitter.com/QuestDX. Additional information for healthcare professionals, including access to ASCLS P.A.C.E.-certified webinars, is available at QuestDiagnostics.com/Education.  

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks are the property of their respective owners.

Quest Diagnostics Contacts:
Dan Haemmerle (Investors): 973-520-2900
Wendy Bost (Media): 973-520-2800


'/>"/>
SOURCE Quest Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
2. U.S. Senate Urged to Increase Federal Funding for Research into Hereditary Angioedema, a Rare and Serious Genetic Disorder
3. AAAS To Host Live Online Discussion On 2013 U.S. Federal R&D Budget
4. The California Healthcare Institute Responds to New Efforts to Repeal the Federal Medical Device Excise Tax
5. BioHealth Innovation, Inc. Launches Program to Help Life Science Companies Navigate Federal Funding Application Process
6. FDA New Guidelines for Biosimilars and Biobetters: An Outlook for 2013
7. Webinar to Discuss Biosimilar Regulatory Guidelines in India and Emerging Markets
8. EU Good Distribution Practice Guidelines
9. How To Get Rid of Bed Bugs Complete Extermination Guidelines Released By My Cleaning Products, Company Announces It's Also Giving Out Samples of Its Bed Bug Spray
10. FDA Advisory Committee Declines to Recommend Approval of Progesterone Vaginal Gel 8% for the Reduction of Risk of Preterm Birth in Women with Short Uterine Cervical Length
11. Urologists Outraged over Government Panels Recommendation to Stop Life-Saving Prostate Cancer Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... ... July 18, 2017 , ... Recently recognized by CIO Magazine ... the migration of its flagship cloud-based product Planet Life Cycle – a robust ... management system that merges strategic and financial planning with execution. The solution is ...
(Date:7/17/2017)... (PRWEB) , ... July 17, ... ... of technology-enabled clinical trial solutions, today announced safety software company AB Cube ... the eHealth Solutions business segment to advance technology innovation across life sciences ...
(Date:7/17/2017)... ... 2017 , ... Panitch Schwarze Belisario & Nadel ... (Biomedical Innovation Group) annual meeting in China. , This year’s meeting, held June ... therapy, a rapidly developing highly personalized anti-cancer technology that involves removing some of ...
(Date:7/16/2017)... ... July 16, 2017 , ... OHAUS ... announced the launch of its new line of Rocking and Waving Shakers today. ... shaker models (both analog and digital) for laboratory applications in a variety of ...
Breaking Biology Technology:
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) is ... tech event dedicated to developing collaboration between startups and global ... June 15-17. During the event, nine startups will showcase the ... in various industries. France ... international market, with a 30 percent increase in the number ...
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
(Date:4/17/2017)... MELBOURNE, Florida , April 17, 2017 ... security technology company, announces the filing of its 2016 Annual Report ... Securities and Exchange Commission. ... Report on Form 10-K is available in the Investor Relations section ... well as on the SEC,s website at http://www.sec.gov . ...
Breaking Biology News(10 mins):